Pembrolizumab and flutamide for advanced head and neck cancer
Part of Cancer clinical trials.
This trial tests a combination of two drugs, pembrolizumab and flutamide, for people with advanced head and neck cancer that has not been treated before. The goal is to see if this combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You have a type of head and neck cancer called squamous cell carcinoma, specifically stage III or IVA that has not spread to distant organs.
- You have not received any prior treatment for this cancer (except for a biopsy).
- You are in good general health (able to do most daily activities without help).
- You have a tumor sample available for testing a protein called PD-L1.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial studies whether pembrolizumab, given before surgery, can improve outcomes for certain people with stage III–IVA head and neck squamous cell cancer. It’s typically added alongside low-dose PFAS as part of treatment leading up to standard surgery and afterward medicines/radiation.
This Phase 2 study tests pembrolizumab (an immunotherapy) plus chemotherapy to treat head and neck cancer that has come back or spread. You might be eligible if standard local treatments won’t be curative and your tumor can be measured on scans.
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.